A Study of GC101 TIL in Advanced Hepatobiliary-Pancreatic Cancers (10hospital)

This study is testing a tumor-infiltrating lymphocyte (TIL) cell therapy — immune cells grown from your own tumor — for people with advanced liver, bile duct, or pancreatic cancers that have stopped responding to standard treatments. **You may be eligible if...** - You have been diagnosed with liver (hepatocellular), bile duct (hepatobiliary), or pancreatic cancer confirmed by biopsy - You are between 18 and 75 years old - You have already tried standard treatments without success, or no standard options are available - You have at least one tumor that can be biopsied or removed to harvest immune cells - Your blood counts and organ function meet the required levels - Your expected survival is at least 3 months **You may NOT be eligible if...** - You have severe organ failure or serious active infections - You are pregnant or breastfeeding - You have no tumor tissue accessible for harvesting TIL cells - Your blood counts are too low to safely proceed Talk to your doctor to see if this trial is right for you.